Age-Related Macular Degeneration and the Complement System: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Niloofar Piri
,
Henry J. Kaplan

Age-related macular degeneration (AMD) is a progressive degenerative disease of the central retina and the leading cause of severe loss of central vision in people over age 50. Patients gradually lose central visual acuity, compromising their ability to read, write, drive, and recognize faces, all of which greatly impact daily life activities. Quality of life is significantly affected in these patients, and there are worse levels of depression as a result. AMD is a complex, multifactorial disease in which age and genetics, as well as environmental factors, all play a role in its development and progression. The mechanism by which these risk factors interact and converge towards AMD are not fully understood, and therefore, drug discovery is challenging, with no successful therapeutic attempt to prevent the development of this disease.

  • age-related macular degeneration
  • AMD
  • complement pathway

1. Introduction

Age-related macular degeneration (AMD) is the leading cause of severe loss of central vision in people over age 50 [1]. It is estimated that nearly 20 million Americans have some form of AMD [2]. Currently, over 200 million people are affected worldwide, and it is estimated that this number will double by 2040 [3][4][5]. In Western countries, nearly 22% of people over 70 and 34% over 80 suffer from AMD in at least one eye [5]. Patients gradually lose central visual acuity, compromising their ability to read, write, drive, and recognize faces, all of which greatly impair their daily life activities [6].

1.1. Anatomy of AMD

The pathology of AMD is restricted to the outer retinal layers and the retinal pigment epithelium (RPE) of the macula [7]. The central macula, or central posterior retina, measures 5 mm in diameter, with the highest density of cone photoreceptors located in the fovea, a 1500-micron area responsible for central visual acuity and color vision [8] (Figure 1). The fovea has a unique anatomical structure, both because of the high density of cone photoreceptors and the absence of retinal blood vessels [9]. The cells in the fovea receive nutrition from the underlying choroidal circulation and the adjacent perifoveal capillary network. The absence of an inner retinal vasculature allows improved light absorption by the cone photoreceptor cells, providing high-resolution vision [10].
Biomolecules 13 00832 g001
Figure 1. Clinical fundus photograph of the macula and fovea and their dimensions.

1.2. Pathophysiology of AMD

Major changes in BM contribute to macular damage, including increased thickness, which is a result of increased deposition and the cross-linking of collagen fibers, and decreased permeability, resulting in decreased RPE metabolic function [10][11][12]. It has also been observed that with aging, there is a deposition of advanced glycated end products (AGEs), i.e., glycated or oxidized lipoproteins [13], which can trigger inflammation, as well as the presence of leukocytes in the choroid underneath the macula in AMD.
RPE cells lose melanosomes, and mitochondria become more prone to oxidative stress with aging [14][15]. This is associated with major changes in the choroid. The normal choroid has high blood flow and can change rapidly, depending on the physiologic demand of the RPE and neurosensory retina. Aging leads to decreased blood flow, as well as the thinning of the choroid [16]. Therefore, flexibility decreases, and the choroid cannot rapidly respond to changes in blood flow required for the physiologic demand. Decreased blood flow results in a decreased support of oxygen and nutrients to the retina. The resultant hypoxia and lack of sufficient nutrient support drives RPE cells to extreme metabolic stress. Additionally, reduced blood flow impairs the removal of photoreceptor and RPE waste products, which are now deposited in the BM, leading to drusen formation [17].
“Drusen” are extracellular deposits between the basal lamina of the RPE and the inner collagenous layer of BM [18][19]. They consist of many different components, and the composition varies with the disease stage. More than 40% of its contents include neutral lipids and esterified and unesterified cholesterol [17]. In addition, more than 129 proteins have been identified in drusen [20], including inflammatory and complement factors, such as vitronectin, serum beta amyloid protein, tissue inhibitor of metalloproteinase 3 (TIMP3), apolipoproteins (E, B, A-I, C-I, and C-II), immunoglobulin light chains, complement proteins (C5 and the C5b-9 complex), proteins involved in complement regulation, and zinc and iron ions [17][20][21].

1.3. Clinical Presentation

Upon clinical examination of the fundus, drusen present as small, yellowish-white spots underneath the retina in the central macula. They are classified clinically in the Wisconsin grading system as hard or soft drusen. Hard drusen are defined as well-defined yellow spots that are 1–63 microns in diameter. Soft drusen are larger than 125 microns, or if they are 63–125 microns, they have visible thickness. Soft drusen can have either distinct or indistinct borders (Figure 2) [22]. They are linked with a higher risk of choroidal neovascularization (CNV) because they include C3a and C5a and can trigger the overexpression of the vascular endothelial growth factor (VEGF) in RPE [23].
Biomolecules 13 00832 g002
Figure 2. (Left) Color fundus photograph of a patient with intermediate AMD demonstrating soft drusen, with indistinct borders. (Right) Optical coherence tomography (OCT) imaging of the central macula in the same patient demonstrating an optical section of all retinal layers. Notice the hyperreflective deposits between the RPE (top arrow)and the BM (bottom arrow), which represent drusen from the left panel.

2. AMD and the Complement System

The complement system is a crucial component of the innate immune response that protects the host against invading pathogens, such as bacteria. It has three pathways: classic (antigen–antibody complex), lectin-dependent (mannose polysaccharides on microorganisms), and alternative (pathogen cell surfaces) [24]. Each pathway has its own distinctive factors, but they all converge and ultimately lead to the cleavage of complement factor 3 (C3) to C3a and C3b. C3a is anaphylatoxin and induces inflammation, and C3b opsonizes cells and labels them for phagocytosis. The complement cascade continues and ultimately forms the membrane attack complex (MAC), which includes (C5b-C9). The MAC penetrates the cell membrane and results in cell death [24][25][26]. The formation of the MAC can be inhibited by complement inhibitors, such as CD59 [27]. Under normal conditions, host cell regulatory proteins deactivate active complement components and prevent damage to host cells [25](Figure 3).
Biomolecules 13 00832 g003
Figure 3. Complement pathways. The alternative pathway is important in AMD. Green triangles demonstrate regulators/inhibitors of the specific pathways. Malfunction will lead to overactivation of complement and, ultimately, cell damage.
The complement system can be considered a double-edged sword. On one side, under normal conditions, it protects the body against foreign pathogens and modifies the surveillance of immune responses; on the other side, under abnormal conditions, its dysregulation or dysfunction can lead to uncontrolled inflammatory responses and can damage host tissue, resulting in disease [28].
The alternative pathway is activated in two different ways. The first one is called “tickover”, which is the spontaneous hydrolysis of C3 into C3 (H2O) in the fluid phase. The second one is by C4b2a (C3 convertase), which results in the cleavage of C3 to C3a and C3b in the solid phase [29]. The alternative pathway is responsible for the majority (80–90%) of the terminal pathway activation [30]; therefore, overactivation of this pathway may have a major role in disease pathogenesis. Early investigations initially debated whether systemic or local complement activation caused disease in the eye. However, it may well be that complement-mediated molecular processes causing AMD are a combination of systemic complement proteins, as well as locally synthesized complement proteins [10]. Experimental studies in animal models suggested the idea above.
The most commonly used animal model mimics wet AMD and is induced by retinal laser photocoagulation in rodents. Laser-induced CNV can be suppressed by blocking complement activation via local or systemic mechanisms. Inhibiting C3a, C5a, CFB, and MAC or administering the complement regulating molecules CD59 and CFH can prevent the formation of CNV in animal models [31][32][33]. In CFH-deficient mice, excessive alternative pathway activation resulted in the enlargement of the induced CNV [34]. It was also shown that mice lacking the alternative complement pathway (CFB-deficient) had decreased rates of CNV, compared to animals lacking other complement pathway constituents [33][35].
In individuals with AMD, several complement system activation products have been identified to be increased systemically [36]. Patients with intermediate or late dry AMD (i.e., central GA or inactive CNV) have higher levels of systemic complement activation, compared to both controls and early AMD [10]. In contrast, the level of systemic complement activation in wet AMD is relatively low [10][36]. Study of donor eyes from patients with the CFH gene showed increased deposits of local C3b before clinical manifestations of the disease. Thus, poorly controlled complement turnover may start earlier than clinical disease manifestation within the retina [36].
Five AMD risk alleles have been recognized involving the alternative complement pathway, implying a role for innate immunity in disease development. Additionally, the pathogenesis of early AMD may be different than that of late-stage AMD [37]. A recent GWAS identified a gene variant near CD46 almost exclusively associated with early AMD [38].
Interestingly, complement products and the membrane attack complex (MAC) have been found in the choroids of eyes from young donors, as well as those without genetic risks for AMD. This suggests that low-grade complement activation is likely required for the normal homeostasis of the retina/RPE complex [10][39][40][41], similar to observations made in the anterior chamber of the eye [42]. The complement system may assist in the removal of waste products, such as the shed photoreceptor outer segments. MAC levels increase with aging, possibly leading to bystander complement-mediated injury of the tissue [10][39][40][41].
A frequent consequence of complement activation is the recruitment and activation of immune cells and the release of the anaphylatoxins C3a and C5a [10]. The immune cells involved in AMD comprise resident microglial cells, as well as circulating lymphocytes, monocytes/macrophages, and mast cells. Stimulation of monocytes by C3a leads to the secretion of multiple cytokines, possibly leading to tissue damage. Mast cell degranulation by C3a and C5a can lead to the release of proteases, tryptase, and chymase, with resultant damage to the extracellular matrix (ECM) [43].
Lipid deposition in the retina has also been linked to both systemic and local complement systems dysregulation [44]. Studies on the serum of AMD patients demonstrated a substantial correlation between elevated large and extra-large high-density lipoprotein (HDL) levels and decreased, very low-density lipoprotein (VLDL) and amino acid levels. These changes were associated with elevated serum complement activation [45].
CFH has been shown to be present in large HDL particles but not in small or medium HDL molecules [46]. Whether this is pro-inflammatory or suppressive for inflammatory responses is not yet clear. Entrapment by HDL might decrease the availability of circulating CFH to deactivate the complement cascade [46]. On the other hand, the presence of CFH in drusen might suppress inflammation locally in the retina. The latter has supportive evidence, since it has been shown that factor H binds the native low-density lipoprotein (LDL) and the oxidized LDL; this binding affinity is reduced in patients with the CFH high-risk 402H variant. As a result, increased levels of oxidized LDL may lead to the upregulation of inflammatory cytokines and the start of an inflammatory cycle that results in tissue damage [47].
It was also observed that disturbed RPE metabolism is important in the pathogenesis of AMD. Compared to RPE cells from healthy controls, primary RPE cells isolated from AMD patients were shown to have severely impaired energy metabolism [48].
Complement dysregulation associated with the CFH variant is associated with reduced energy metabolism in RPE cells [49]. Complement dysregulation was associated with mitochondrial damage in RPE cells [50]. Compared to RPE cells from donors with the low-risk 402Y genetic variation, RPE cells from AMD donors harboring the high-risk 402H variant exhibited greater mtDNA damage [50]. In the CFH (cfh-/-) knock-out mouse model, abnormally large mitochondria were shown in the RPE and photoreceptors. At the same time, the amount of mitochondrial DNA (mt DNA) decreased, which is a sign of energy dysregulation confirmed by lower adenosine tri-phosphate (ATP) production [49]. Regarding an oxidative stress response, there seems to be a reciprocal interaction between the complement system control and energy metabolism [10]. In a cytoplasmic hybrid (cybrid) model, with mitochondria from AMD patients and ARPE19 devoid of mitochondria, changes in complement components were demonstrated. Complement activators, including CFB, were found to be increased, and complement inhibitors, including CFH, were found to be decreased [51].

This entry is adapted from the peer-reviewed paper 10.3390/biom13050832

References

  1. Lim, L.S.; Mitchell, P.; Seddon, J.M.; Holz, F.G.; Wong, T.Y. Age-related macular degeneration. Lancet 2012, 379, 1728–1738.
  2. Rein, D.B.; Wittenborn, J.S.; Burke-Conte, Z.; Gulia, R.; Robalik, T.; Ehrlich, J.R.; Lundeen, E.A.; Flaxman, A.D. Prevalence of Age-Related Macular Degeneration in the US in 2019. JAMA Ophthalmol. 2022, 140, 1202–1208.
  3. Li, J.Q.; Welchowski, T.; Schmid, M.; Mauschitz, M.M.; Holz, F.G.; Finger, R.P. Prevalence and incidence of age-related macular degeneration in Europe: A systematic review and meta-analysis. Br J. Ophthalmol. 2020, 104, 1077–1084.
  4. Colijn, J.M.; Buitendijk, G.H.S.; Prokofyeva, E.; Alves, D.; Cachulo, M.L.; Khawaja, A.P.; Cougnard-Gregoire, A.; Merle, B.M.J.; Korb, C.; Erke, M.G.; et al. Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future. Ophthalmology 2017, 124, 1753–1763.
  5. Wong, W.L.; Su, X.; Li, X.; Cheung, C.M.; Klein, R.; Cheng, C.Y.; Wong, T.Y. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob. Health 2014, 2, e106-116.
  6. Coleman, A.L.; Yu, F.; Ensrud, K.E.; Stone, K.L.; Cauley, J.A.; Pedula, K.L.; Hochberg, M.C.; Mangione, C.M. Impact of age-related macular degeneration on vision-specific quality of life: Follow-up from the 10-year and 15-year visits of the Study of Osteoporotic Fractures. Am. J. Ophthalmol. 2010, 150, 683–691.
  7. Coleman, H.R.; Chan, C.C.; Ferris, F.L., 3rd; Chew, E.Y. Age-related macular degeneration. Lancet 2008, 372, 1835–1845.
  8. Curcio, C.A.; Medeiros, N.E.; Millican, C.L. Photoreceptor loss in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 1996, 37, 1236–1249.
  9. Chen, M.; Xu, H. Parainflammation, chronic inflammation, and age-related macular degeneration. J. Leukoc. Biol. 2015, 98, 713–725.
  10. Armento, A.; Ueffing, M.; Clark, S.J. The complement system in age-related macular degeneration. Cell. Mol. Life Sci. 2021, 78, 4487–4505.
  11. Ramrattan, R.S.; van der Schaft, T.L.; Mooy, C.M.; de Bruijn, W.C.; Mulder, P.G.; de Jong, P.T. Morphometric analysis of Bruch’s membrane, the choriocapillaris, and the choroid in aging. Invest. Ophthalmol. Vis. Sci. 1994, 35, 2857–2864.
  12. Hjelmeland, L.M.; Cristofolo, V.J.; Funk, W.; Rakoczy, E.; Katz, M.L. Senescence of the retinal pigment epithelium. Mol. Vis. 1999, 5, 33.
  13. Booij, J.C.; Baas, D.C.; Beisekeeva, J.; Gorgels, T.G.; Bergen, A.A. The dynamic nature of Bruch’s membrane. Prog. Retin. Eye Res. 2010, 29, 1–18.
  14. Feher, J.; Kovacs, I.; Artico, M.; Cavallotti, C.; Papale, A.; Balacco Gabrieli, C. Mitochondrial alterations of retinal pigment epithelium in age-related macular degeneration. Neurobiol. Aging 2006, 27, 983–993.
  15. Brown, E.E.; DeWeerd, A.J.; Ildefonso, C.J.; Lewin, A.S.; Ash, J.D. Mitochondrial oxidative stress in the retinal pigment epithelium (RPE) led to metabolic dysfunction in both the RPE and retinal photoreceptors. Redox Biol. 2019, 24, 101201.
  16. Wakatsuki, Y.; Shinojima, A.; Kawamura, A.; Yuzawa, M. Correlation of Aging and Segmental Choroidal Thickness Measurement using Swept Source Optical Coherence Tomography in Healthy Eyes. PLoS ONE 2015, 10, e0144156.
  17. Curcio, C.A.; Johnson, M.; Huang, J.D.; Rudolf, M. Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins. Prog. Retin. Eye Res. 2009, 28, 393–422.
  18. Hageman, G.S.; Luthert, P.J.; Victor Chong, N.H.; Johnson, L.V.; Anderson, D.H.; Mullins, R.F. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye Res. 2001, 20, 705–732.
  19. Hageman, G.S.; Mullins, R.F. Molecular composition of drusen as related to substructural phenotype. Mol. Vis. 1999, 5, 28.
  20. Rudolf, M.; Clark, M.E.; Chimento, M.F.; Li, C.M.; Medeiros, N.E.; Curcio, C.A. Prevalence and morphology of druse types in the macula and periphery of eyes with age-related maculopathy. Invest. Ophthalmol. Vis. Sci. 2008, 49, 1200–1209.
  21. Mullins, R.F.; Russell, S.R.; Anderson, D.H.; Hageman, G.S. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. Faseb J. 2000, 14, 835–846.
  22. Klein, R.; Davis, M.D.; Magli, Y.L.; Segal, P.; Klein, B.E.; Hubbard, L. The Wisconsin age-related maculopathy grading system. Ophthalmology 1991, 98, 1128–1134.
  23. Miao, H.; Tao, Y.; Li, X.X. Inflammatory cytokines in aqueous humor of patients with choroidal neovascularization. Mol. Vis. 2012, 18, 574–580.
  24. Park, Y.G.; Park, Y.S.; Kim, I.B. Complement System and Potential Therapeutics in Age-Related Macular Degeneration. Int. J. Mol. Sci. 2021, 22, 6851.
  25. Boyer, D.S.; Schmidt-Erfurth, U.; van Lookeren Campagne, M.; Henry, E.C.; Brittain, C. The Pathophysiology of Geographic Atrophy Secondary to Age-Related Macular Degeneration and the Complement Pathway as a Therapeutic Target. Retina 2017, 37, 819–835.
  26. Schramm, E.C.; Clark, S.J.; Triebwasser, M.P.; Raychaudhuri, S.; Seddon, J.; Atkinson, J.P. Genetic variants in the complement system predisposing to age-related macular degeneration: A review. Mol. Immunol. 2014, 61, 118–125.
  27. Morgan, B.P.; Walters, D.; Serna, M.; Bubeck, D. Terminal complexes of the complement system: New structural insights and their relevance to function. Immunol. Rev. 2016, 274, 141–151.
  28. Qin, S.; Dong, N.; Yang, M.; Wang, J.; Feng, X.; Wang, Y. Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option. J. Immunol. Res. 2021, 2021, 9945725.
  29. Kim, B.J.; Mastellos, D.C.; Li, Y.; Dunaief, J.L.; Lambris, J.D. Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions. Prog. Retin. Eye Res. 2021, 83, 100936.
  30. Harboe, M.; Ulvund, G.; Vien, L.; Fung, M.; Mollnes, T.E. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 2004, 138, 439–446.
  31. Kim, S.J.; Kim, J.; Lee, J.; Cho, S.Y.; Kang, H.J.; Kim, K.Y.; Jin, D.K. Intravitreal human complement factor H in a rat model of laser-induced choroidal neovascularisation. Br J. Ophthalmol. 2013, 97, 367–370.
  32. Bora, N.S.; Jha, P.; Lyzogubov, V.V.; Kaliappan, S.; Liu, J.; Tytarenko, R.G.; Fraser, D.A.; Morgan, B.P.; Bora, P.S. Recombinant membrane-targeted form of CD59 inhibits the growth of choroidal neovascular complex in mice. J. Biol. Chem. 2010, 285, 33826–33833.
  33. Nozaki, M.; Raisler, B.J.; Sakurai, E.; Sarma, J.V.; Barnum, S.R.; Lambris, J.D.; Chen, Y.; Zhang, K.; Ambati, B.K.; Baffi, J.Z.; et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc. Natl. Acad. Sci. USA 2006, 103, 2328–2333.
  34. Lundh von Leithner, P.; Kam, J.H.; Bainbridge, J.; Catchpole, I.; Gough, G.; Coffey, P.; Jeffery, G. Complement factor h is critical in the maintenance of retinal perfusion. Am. J. Pathol. 2009, 175, 412–421.
  35. Rohrer, B.; Long, Q.; Coughlin, B.; Wilson, R.B.; Huang, Y.; Qiao, F.; Tang, P.H.; Kunchithapautham, K.; Gilkeson, G.S.; Tomlinson, S. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2009, 50, 3056–3064.
  36. Heesterbeek, T.J.; Lechanteur, Y.T.E.; Lorés-Motta, L.; Schick, T.; Daha, M.R.; Altay, L.; Liakopoulos, S.; Smailhodzic, D.; den Hollander, A.I.; Hoyng, C.B.; et al. Complement Activation Levels Are Related to Disease Stage in AMD. Invest. Ophthalmol. Vis. Sci. 2020, 61, 18.
  37. Merle, B.M.J.; Colijn, J.M.; Cougnard-Gregoire, A.; de Koning-Backus, A.P.M.; Delyfer, M.N.; Kiefte-de Jong, J.C.; Meester-Smoor, M.; Feart, C.; Verzijden, T.; Samieri, C.; et al. Mediterranean Diet and Incidence of Advanced Age-Related Macular Degeneration: The EYE-RISK Consortium. Ophthalmology 2019, 126, 381–390.
  38. Winkler, T.W.; Grassmann, F.; Brandl, C.; Kiel, C.; Günther, F.; Strunz, T.; Weidner, L.; Zimmermann, M.E.; Korb, C.A.; Poplawski, A.; et al. Genome-wide association meta-analysis for early age-related macular degeneration highlights novel loci and insights for advanced disease. BMC Med. Genom. 2020, 13, 120.
  39. Mullins, R.F.; Schoo, D.P.; Sohn, E.H.; Flamme-Wiese, M.J.; Workamelahu, G.; Johnston, R.M.; Wang, K.; Tucker, B.A.; Stone, E.M. The membrane attack complex in aging human choriocapillaris: Relationship to macular degeneration and choroidal thinning. Am. J. Pathol. 2014, 184, 3142–3153.
  40. Keenan, T.D.; Toso, M.; Pappas, C.; Nichols, L.; Bishop, P.N.; Hageman, G.S. Assessment of Proteins Associated With Complement Activation and Inflammation in Maculae of Human Donors Homozygous Risk at Chromosome 1 CFH-to-F13B. Invest. Ophthalmol. Vis. Sci. 2015, 56, 4870–4879.
  41. Whitmore, S.S.; Sohn, E.H.; Chirco, K.R.; Drack, A.V.; Stone, E.M.; Tucker, B.A.; Mullins, R.F. Complement activation and choriocapillaris loss in early AMD: Implications for pathophysiology and therapy. Prog. Retin. Eye Res. 2015, 45, 1–29.
  42. Sohn, J.H.; Kaplan, H.J.; Suk, H.J.; Bora, P.S.; Bora, N.S. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. Invest. Ophthalmol. Vis. Sci. 2000, 41, 3492–3502.
  43. Lohman, R.-J.; Hamidon, J.K.; Reid, R.C.; Rowley, J.A.; Yau, M.-K.; Halili, M.A.; Nielsen, D.S.; Lim, J.; Wu, K.-C.; Loh, Z.; et al. Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a. Nat. Commun. 2017, 8, 351.
  44. Landowski, M.; Kelly, U.; Klingeborn, M.; Groelle, M.; Ding, J.D.; Grigsby, D.; Bowes Rickman, C. Human complement factor H Y402H polymorphism causes an age-related macular degeneration phenotype and lipoprotein dysregulation in mice. Proc. Natl. Acad. Sci. USA 2019, 116, 3703–3711.
  45. Acar İ, E.; Lores-Motta, L.; Colijn, J.M.; Meester-Smoor, M.A.; Verzijden, T.; Cougnard-Gregoire, A.; Ajana, S.; Merle, B.M.J.; de Breuk, A.; Heesterbeek, T.J.; et al. Integrating Metabolomics, Genomics, and Disease Pathways in Age-Related Macular Degeneration: The EYE-RISK Consortium. Ophthalmology 2020, 127, 1693–1709.
  46. Zhang, Y.; Gordon, S.M.; Xi, H.; Choi, S.; Paz, M.A.; Sun, R.; Yang, W.; Saredy, J.; Khan, M.; Remaley, A.T.; et al. HDL subclass proteomic analysis and functional implication of protein dynamic change during HDL maturation. Redox Biol. 2019, 24, 101222.
  47. Shaw, P.X.; Zhang, L.; Zhang, M.; Du, H.; Zhao, L.; Lee, C.; Grob, S.; Lim, S.L.; Hughes, G.; Lee, J.; et al. Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids. Proc. Natl. Acad. Sci. USA 2012, 109, 13757–13762.
  48. Ferrington, D.A.; Ebeling, M.C.; Kapphahn, R.J.; Terluk, M.R.; Fisher, C.R.; Polanco, J.R.; Roehrich, H.; Leary, M.M.; Geng, Z.; Dutton, J.R.; et al. Altered bioenergetics and enhanced resistance to oxidative stress in human retinal pigment epithelial cells from donors with age-related macular degeneration. Redox Biol. 2017, 13, 255–265.
  49. Sivapathasuntharam, C.; Hayes, M.J.; Shinhmar, H.; Kam, J.H.; Sivaprasad, S.; Jeffery, G. Complement factor H regulates retinal development and its absence may establish a footprint for age related macular degeneration. Sci. Rep. 2019, 9, 1082.
  50. Ferrington, D.A.; Kapphahn, R.J.; Leary, M.M.; Atilano, S.R.; Terluk, M.R.; Karunadharma, P.; Chen, G.K.; Ratnapriya, R.; Swaroop, A.; Montezuma, S.R.; et al. Increased retinal mtDNA damage in the CFH variant associated with age-related macular degeneration. Exp. Eye Res. 2016, 145, 269–277.
  51. Nashine, S.; Chwa, M.; Kazemian, M.; Thaker, K.; Lu, S.; Nesburn, A.; Kuppermann, B.D.; Kenney, M.C. Differential Expression of Complement Markers in Normal and AMD Transmitochondrial Cybrids. PLoS One 2016, 11, e0159828.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback